Optibiotix Health Share Discussion Threads

[pol123] 21/2/2019 07:53

The story is just getting stronger and stronger

[parob] 21/2/2019 07:53

I have just remembered this comment from SOH a couple of weeks ago. This news looks like a precursor to some big deals coming out of the US.hTTps://lemminginvestors.blogspot.com/2019/02/the-run-rate-for-optibiotix-health-opti.htmlCommenting on this Stephen O'Hara; "With our deal pipeline, extending our products into new application areas (Dairy for LP-LDL), SlimBiome Medical, and geographies (Japan), BIGGER DEALS in the USA, retail opportunities, online sales growing rapidly as we invest in marketing (Daily Mail, Telegraph, and Guardian to come) and of course SweetBiotix and our prebiotics coming on line I am increasingly confident of the future."

[nobbygnome] 21/2/2019 07:46

I have just taken my LPLDL in my Cholbiome pill.....and can confirm it is perfectly safe😜

[1crackupboom] 21/2/2019 07:45

This would always get GRAS. Nothing exciting

[riskybusiness1] 21/2/2019 07:38

Not only does this mean LPLDL can be used in dairy etc in US this will significantly speed up the US drug development and allow the company to skip to phase 3.

[ramas] 21/2/2019 07:38

Just like ARM I expect OPTI to founder in the 100p range for a while yet but ultimately it it keeps delivering there will be a boom moment when realisation strikes and I don't see why we won't be a five bagger probably more .... not there just yet though

[parob] 21/2/2019 07:38

What is LPLDL®?A true breakthrough in innovative health product development, OptiBiotix's Lactobacillus plantarum LPLDL® is a next-generation probiotic that aids elements of cardiovascular and wellbeing.LPLDL® has been shown in randomised, placebo controlled human intervention studies to deliver tangible health benefits, reducing cardiovascular risk factors and supporting overall heart wellness. These include: • Lower total cholesterol by up to 36.7% • Lower LDL cholesterol by up to 13.9% • Increase HDL cholesterol by up to 6.5% • Lower systolic blood pressure by 5.1% • Be completely safe and well tolerated

[imnotlong] 21/2/2019 07:38

Risky, does Lpldl need a similar status to be used in food and drink in the EU?

Or can it already be used in that way in the EU?

[rayrac] 21/2/2019 07:36

Meaningless totally.

“Expands the use to HIGH VALUE MEDICAL FOOD applications.”

Only if it works better than the percentages shown on this thread...5.1%bp..13.9% cholesterol.

[parob] 21/2/2019 07:33

As we have been stuck in a trading range the share price doesn't reflect the deals and remarkable progress that has been made since the start of the year. Not long now until we see that value realised. IMO a powerful breakout is on the cards soon.

[woodaldo] 21/2/2019 07:25

Another huge piece of the jigsaw just fitted into place. Love SOH comment at the end

"In addition, obtaining GRAS status is increasingly being seen by large US corporates as a key requirement to independently validate the safety of commercial probiotic strains in supplements and as such, is a major point of differentiation from other probiotics, as very few strains currently have this status."

Sums it up, big boys come out to play in the US when GRAS status is achieved.

[riskybusiness1] 21/2/2019 07:19

Massive news.

[parob] 21/2/2019 07:16

AMAZING NEWS!The USA is one of the largest and fastest growing probiotic markets in the world with sales in 2016 of supplements accounting for $2.06 billion, and food and beverage products $5bn per annum*.So the US market for LP-LDL has more than tripled!Expands the use to HIGH VALUE MEDICAL FOOD applications. Well done Luís and team!

[aspex] 21/2/2019 07:15

Keep it quiet today please. Just found a few pennies to top up.

[best1467] 21/2/2019 07:15

Would have to agree in my opinion most significant news for some time Will give massive
Leverage in any future negotiations as only company to date granted this status which as they say taken two years to achieve and quite costly.

[nobbygnome] 21/2/2019 07:14

From my Pharma experience, I can tell you this is massive particularly for the company doing the clinical trials. It means proving safety in those trials is not something they need to worry about any more.

[judijudi] 21/2/2019 07:10

FFS not again
RK Filtered for being a Child

[reckless kelly] 21/2/2019 07:07

No doubt in my mind this is an absolutely stunning announcement !

1) Vote up if you agree
2) Vote down if you're as thick as 2 short planks.

LOL

[rafboy] 21/2/2019 07:06

We are so going places. Well done OPTI, another major step forward.

[judijudi] 21/2/2019 07:04

Fantastic news yet again

[someuwin] 21/2/2019 07:03

OptiBiotix Health plc
("OptiBiotix" or the "Company")

LPLDL® determined GRAS by an Expert Panel in the United States

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that ProBiotix Health Ltd, its fully-owned subsidiary, has had its cholesterol and blood pressure reducing Lactobacillus plantarum LPLDL® probiotic strain determined as Generally Recognized As Safe ("GRAS") by an independent Expert GRAS Panel in the United States.

GRAS is a United States Food and Drug Administration (FDA) designation that any substance added to food is considered safe by experts. GRAS status is therefore required for the use of these substances in foods. In the case of probiotics, it is a strain-specific process in which all strains not described before 1958 - as is the case of LPLDL® - must be categorised as GRAS if they are to be added to foods. GRAS assessment involves submitting an extensive technical dossier for evaluation by an independent panel of experts. They confirm if the ingredient is safe, under what conditions it can be used, and for which applications.

The Expert GRAS Panel that reviewed the LPLDL® dossier was formed by international experts in toxicology, pharmacology and regulatory affairs. After evaluating information on LPLDL®'s science, genetic composition, lack of antibiotic resistance, human clinical study results and market feedback, the Panel members concluded that the evidence was sufficient to determine that LPLDL® is safe for use in food and beverage categories at a concentration of up to 10 billion colony forming units (CFU) per serving. This is more than double the dose found to significantly reduce cholesterol and blood pressure in the human trial conducted by Reading University (Costabile et al., 2017).

The process of GRAS determination has taken over two years of work, led by OptiBiotix's Business Development Director, Dr. Luis Gosalbez. Compiling the GRAS dossier has involved the generation of large amounts of laboratory data, genetic analyses, and an extensive review of the scientific literature. Whilst a costly and time-consuming process, it extends the potential applications of LPLDL® to use as a functional ingredient in food, dairy, and beverage products across the USA.

This is a strategic step by OptiBiotix to extend the market opportunity within the US probiotic market to food, dairy, and beverage products. The USA is one of the largest and fastest growing probiotic markets in the world with sales in 2016 of supplements accounting for $2.06 billion, and food and beverage products $5bn per annum*.

(*Market data from 'TRENDS, INNOVATIONS AND OPPORTUNITIES DRIVING THE GLOBAL PROBIOTICS MARKET' (Euromonitor International June 2017)

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce that the independent Expert Panel has ruled in favour of LPLDL®'s GRAS status. This is a significant achievement and a major commercial milestone as it expands the potential applications of LPLDL® from use as a supplement to use as a functional ingredient in a wide range of food, dairy, beverage, and high value medical food applications, across the USA. In addition, obtaining GRAS status is increasingly being seen by large US corporates as a key requirement to independently validate the safety of commercial probiotic strains in supplements and as such, is a major point of differentiation from other probiotics, as very few strains currently have this status.

[nobbygnome] 20/2/2019 21:03

Right products, right place, right time. Can't say more than that....

[parob] 20/2/2019 21:00

Sweetbiotix - from the RNS:The results showed significant increases in short-chain fatty acids ("SCFA"), the molecular messengers produced by bacteria when they ferment fibre and non-digestible carbohydrates. SCFA are widely known for their importance in gut health, immunity and affect how energy is metabolised in the body, and are one of the main ways in which the gut microbiome contributes to better health.-----Our resident doctor in the lemmings group ( hTTps://groups.google.com/forum/m/#!forum/lemminginvestors ) Adnan who used to post here posted an interesting article on the role of short chain fatty acids in improving diabetes:?hTTps://www.hindawi.com/journals/mi/2014/162021/?So what we have is a healthy sweetener which may contribute to improved diabetic control. Does make you wonder what OPTI will discovery next.Truly revolutionary products!

[shrewdmole] 20/2/2019 19:28

And I wonder where our research is goi with the physchobiotics?!?!